← Back to Search

Other

LY3841136 for Obesity

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose through week 14 (part a) & week 28 (part b)
Awards & highlights

Study Summary

This trial is testing a new drug for safety and how well it is tolerated. Blood tests will be performed to check how much of the drug gets into the bloodstream and how long it takes the body to eliminate it. The trial will last up to 28 weeks and include 19 visits.

Who is the study for?
This trial is for healthy or overweight males and non-childbearing potential females with a stable weight. Participants must have a BMI of 18.5-32 kg/m² (Part A) or 27-40 kg/m² (Part B). They should agree to use contraception. Those with diabetes, lactating women, allergies to LY3841136 components, significant heart/liver/kidney diseases, severe allergies, or drug hypersensitivity cannot join.Check my eligibility
What is being tested?
The study tests the safety and how the body processes LY3841136 in two parts over up to 14 weeks (Part A) and up to 28 weeks (Part B), involving multiple visits. It compares LY3841136 against a placebo in healthy and overweight individuals through blood tests.See study design
What are the potential side effects?
While specific side effects are not listed here, common ones may include reactions at the injection site, nausea, headaches, fatigue or allergic reactions. The study aims to assess these by monitoring participants' tolerance.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 14 weeks (part a) & 28 weeks (part b)
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 14 weeks (part a) & 28 weeks (part b) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
PK: Maximum Observed Concentration (Cmax) of LY3841136
Pharmacodynamics (PD): Change From Baseline in Body Weight
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3841136

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3841136 (Part B)Experimental Treatment1 Intervention
Multiple ascending doses of LY3841136 administered SC.
Group II: LY3841136 (Part A)Experimental Treatment1 Intervention
Single ascending doses of LY3841136 administered subcutaneously (SC).
Group III: Placebo (Part A)Placebo Group1 Intervention
Placebo administered SC.
Group IV: Placebo (Part B)Placebo Group1 Intervention
Placebo administered SC.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,603 Previous Clinical Trials
3,199,470 Total Patients Enrolled
51 Trials studying Obesity
40,526 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,336 Previous Clinical Trials
403,645 Total Patients Enrolled
34 Trials studying Obesity
20,245 Patients Enrolled for Obesity

Media Library

LY3841136 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05295940 — Phase 1
Obesity Research Study Groups: LY3841136 (Part B), LY3841136 (Part A), Placebo (Part A), Placebo (Part B)
Obesity Clinical Trial 2023: LY3841136 Highlights & Side Effects. Trial Name: NCT05295940 — Phase 1
LY3841136 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05295940 — Phase 1
Obesity Patient Testimony for trial: Trial Name: NCT05295940 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of individuals would be suitable candidates for this medical experiment?

"This clinical trial is recruiting 160 individuals aged 18-65 with obesity. Notably, male patients must consent to using reliable forms of contraception, female applicants must be infertile and all participants should have maintained a stable weight for the last three months and possess a BMI between 18.5 - 32 kg/m² in Part A or 27 – 40kg/m² in Part B."

Answered by AI

What is the current size of this medical experiment's participant pool?

"To complete this trial, 160 individuals that meet the criteria need to sign up. Patient recruitment is available across locations like LabCorp CRU, Inc in Daytona Beach and Covance Dallas in Texas."

Answered by AI

Has the Food and Drug Administration given its stamp of approval to LY3841136?

"The safety of LY3841136 is rated as 1 on our internal scale due to the fact that this study only has initial evidence regarding its efficacy and safety."

Answered by AI

Is this trial actively seeking participants?

"Affirmative. The information posted on clinicaltrials.gov conveys that recruitment for this trial is still ongoing, having first been announced back in March 30th 2022 and being updated as recently as November 22nd 2022. 160 test subjects are required across 3 distinct sites for the study to be successful."

Answered by AI

Does this research have an age cut-off for participant inclusion?

"To be accepted into this trial, applicants must fall between the ages of 18 and 65. For those younger than 18 or older seniors aged 65+, there are 272 studies available for minors and 1059 clinical trials tailored to elders."

Answered by AI

Who else is applying?

What state do they live in?
Missouri
Other
Wisconsin
Texas
How old are they?
18 - 65
What site did they apply to?
Fortrea Clinical Research Unit
Covance Clinical Research Unit
Covance Dallas
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
2
3+
0

What questions have other patients asked about this trial?

Can the screening visits be scheduled around my regular workday?
PatientReceived 2+ prior treatments

Why did patients apply to this trial?

I am looking to volunteer. I've tried phentermine, contrave & qsymia for weigh loss.
PatientReceived 1 prior treatment
I'm hoping this clinical trial will help my medical condition. I sign up for trials periodically for the sake of aiding medical research.
PatientReceived no prior treatments
I've tried multiple things to lose weight but nothing seems to help me lose weight.
PatientReceived no prior treatments
~55 spots leftby Mar 2025